Literature DB >> 26748958

Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine.

A M Cameron1, R N Wesson1, A R Ahmadi1, A L Singer1,2, X Hu1,3, T Okabayashi1,4, Y Wang1, M Shigoka1,5, Y Fu1,6, W Gao1,6, L C Raccusen7, R A Montgomery1, G M Williams1, Z Sun1.   

Abstract

Transplantation is now lifesaving therapy for patients with end-stage organ failure but requires lifelong immunosuppression with resultant morbidity. Current immunosuppressive strategies inhibit T cell activation and prevent donor-recipient engagement. Therefore, it is not surprising that few host cells are demonstrated in donor grafts. However, our recent small animal studies found large numbers of recipient stem cells present after transplantation and pharmacological mobilization, resulting in a chimeric, repopulated organ. We now confirm these findings in a well-characterized large animal preclinical model. Here, we show that AMD3100 and FK506 mobilization of endogenous stem cells immediately post kidney transplantation combined with repeat therapy at 1, 2, and 3 months led to drug-free long-term survival in maximally immunologically mismatched swine. Three long-term recipients have stable chimeric transplants, preserved antidonor skin graft responses, and normal serum creatinine levels despite withdrawal of all medication for 3 years. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  animal models: porcine; basic (laboratory) research/science; immune regulation; kidney failure/injury; kidney transplantation/nephrology; pathology/histopathology; regenerative medicine; stem cells; tolerance; translational research/science

Mesh:

Substances:

Year:  2016        PMID: 26748958     DOI: 10.1111/ajt.13703

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

1.  Transplantation: Reverse chimerism enables graft acceptance.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2016-01-25       Impact factor: 28.314

2.  Activation of BMP Signaling by FKBP12 Ligands Synergizes with Inhibition of CXCR4 to Accelerate Wound Healing.

Authors:  Brandon J Peiffer; Le Qi; Ali R Ahmadi; Yuefan Wang; Zufeng Guo; Hanjing Peng; Zhaoli Sun; Jun O Liu
Journal:  Cell Chem Biol       Date:  2019-02-28       Impact factor: 8.116

3.  Reproducible porcine model for kidney allotransplantation of low weight miniature pig.

Authors:  Min Zhang; Xin Zheng; Xin Zhang; Zijian Zhang; Xin Wang; Xiaopeng Hu
Journal:  Transl Androl Urol       Date:  2022-04

4.  Production of a Locus- and Allele-Specific Monoclonal Antibody for the Characterization of SLA-1*0401 mRNA and Protein Expression Levels in MHC-Defined Microminipigs.

Authors:  Yoshie Kametani; Shino Ohshima; Asuka Miyamoto; Atsuko Shigenari; Masaki Takasu; Noriaki Imaeda; Tatsuya Matsubara; Masafumi Tanaka; Takashi Shiina; Hiroshi Kamiguchi; Ryuji Suzuki; Hitoshi Kitagawa; Jerzy K Kulski; Noriaki Hirayama; Hidetoshi Inoko; Asako Ando
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

5.  SDF‑1/CXCR4 induces epithelial‑mesenchymal transition through activation of the Wnt/β‑catenin signaling pathway in rat chronic allograft nephropathy.

Authors:  Hao Tang; Yue Xu; Zijian Zhang; Song Zeng; Wenbo Dong; Wenjiao Jiao; Xiaopeng Hu
Journal:  Mol Med Rep       Date:  2019-03-15       Impact factor: 2.952

6.  Pharmacological Mobilization of Endogenous Bone Marrow Stem Cells Promotes Liver Regeneration after Extensive Liver Resection in Rats.

Authors:  Rujun Zhai; Yongchun Wang; Le Qi; George Melville Williams; Bin Gao; Guang Song; James F Burdick; Zhaoli Sun
Journal:  Sci Rep       Date:  2018-02-26       Impact factor: 4.379

7.  Stromal cell-derived factor-1/CXC chemokine receptor 4 axis in injury repair and renal transplantation.

Authors:  Zejia Sun; Xin Li; Xiang Zheng; Peng Cao; Baozhong Yu; Wei Wang
Journal:  J Int Med Res       Date:  2019-10-03       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.